UroGen Pharma Ltd (URGN) — Cash Flow Reinvestment Rate

Latest as of September 2017: 13.87x

UroGen Pharma Ltd (URGN) has a Cash Flow Reinvestment Rate of 13.87x as of September 2017, reinvesting $36.02 Million (capex $20.00K plus investments $-36.00 Million) from operating cash flow of $2.60 Million. Explore capital reinvestment ratio of UroGen Pharma Ltd to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

13.87x

(Capex + Investments) / Operating CF

Total Reinvested

$36.02 Million

Capex + Investments

Operating Cash Flow

$2.60 Million

USD

Capital Expenditures

$20.00K

USD

UroGen Pharma Ltd Cash Flow Reinvestment Rate (2016–2016)

Historical reinvestment intensity for UroGen Pharma Ltd across 1 annual periods. Also explore total assets of UroGen Pharma Ltd for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for UroGen Pharma Ltd (2016–2016)

Year-by-year capital reinvestment analysis for UroGen Pharma Ltd. For live market cap and broader valuation context, see URGN market cap.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2016	0.36x	$1.49 Million	$4.19 Million	$695.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow